Gevel-M 2 Tablet PR is a combination oral antihyperglycemic medication containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, enhances pancreatic insulin secretion, thereby reducing blood glucose levels, while Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity. This dual mechanism addresses both insulin deficiency and insulin resistance, making Gevel-M 2 effective in achieving glycemic control in patients inadequately managed by diet and exercise alone. The prolonged-release formulation ensures a steady plasma concentration, improving patient compliance and minimizing gastrointestinal side effects commonly associated with Metformin. Gevel-M 2 is recommended as an adjunct to lifestyle modifications, including diet and physical activity. It should be used cautiously in patients with renal impairment, hepatic dysfunction, or cardiovascular disease, and contraindicated in those with known hypersensitivity to its components or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose, renal function, and liver enzymes is advised during therapy. Dose adjustments may be necessary based on therapeutic response and tolerability. Gevel-M 2 Tablet PR offers a convenient and effective option for optimizing glycemic control in type 2 diabetes mellitus patients.

Dosage & How to Use